The early reported anti-Trop2 bispecific antibodies are bispecific T cell engagers (BiTEs) that use CD3 as a target to redirect T cells towards Trop2-expressing tumor cells (Figure 3). The gene discussed is TACSTD2; the disease is neoplasm.